Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O00560
UPID:
SDCB1_HUMAN
Alternative names:
Melanoma differentiation-associated protein 9; Pro-TGF-alpha cytoplasmic domain-interacting protein 18; Scaffold protein Pbp1; Syndecan-binding protein 1
Alternative UPACC:
O00560; B2R5Q7; B4DUH3; B7ZLN2; O00173; O43391; Q14CP2
Background:
Syntenin-1, known for its roles in transmembrane protein trafficking, neuro and immunomodulation, exosome biogenesis, and tumorigenesis, is a multifunctional adapter protein. It enhances TGFB1 signaling, contributing to cell migration and epithelial-to-mesenchymal transition across various cell types. Additionally, it plays a pivotal role in cancer progression, influencing migration, growth, and cell cycle. Syntenin-1's interaction with the IL-5 receptor and involvement in vesicular trafficking underscore its complex biological functions.
Therapeutic significance:
Understanding the role of Syntenin-1 could open doors to potential therapeutic strategies.